FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978590976> ?p ?o ?g. }

• W1978590976 endingPage "1148" @default.
• W1978590976 startingPage "1143" @default.
• W1978590976 abstract "Kaposi's sarcoma (KS), the most common malignancy associated with HIV infection, is caused by the Kaposi sarcoma herpesvirus (KSHV). Exacerbations of KSHV are associated with increased human interleukin-6 (HuIL-6), and elevated IL-6 could be related to the development of KS. IL-4, a cytokine with pleiotropic effects, suppresses IL-6 in vivo and modestly inhibits AIDS-KS-derived cells in vitro. Suppression of IL-6 by exogenous IL-4 could result in antitumor activity. We report the results of a clinical trial to test this hypothesis. A phase I/II dose escalation safety, tolerance, and efficacy trial was conducted in patients with biopsy-proven AIDS-related KS, at two university medical centers. Patients were scheduled to receive IL-4 (0.5, 1.5, 3.0, or 4.0 μg/kg/day) administered subcutaneously (s.c.) in sequential cohorts. Patients were continued on study as long as the drug was tolerated or the disease progressed. Patients were followed for antitumor activity, effects on viral replication, immune status, and clinical and laboratory toxicity. Seventeen patients were enrolled at two sites over a 21-month period. There were 15 males and 2 females, and 1 patient was Hispanic. All patients had a Karnofsky score >70. Patients enrolled only into the two lower dose cohorts (0.5 and 1.5 μg/kg/day). Both groups had similar baseline characteristics. The median time on treatment was only 7.4 and 8.4 weeks for the 0.5 and 1.5 μg/kg/day dose levels, respectively. There was significant neutropenia, with 6 patients having grade 3 or greater toxicity requiring granulocyte colony-stimulating factor (G-CSF). Three patients on a dose of 1.5 μg/kg/day stopped treatment due to protocol-defined toxicity. There were no appreciable effects on CD4/CD8 counts. HIV viral RNA did not significantly change over time. However, in several people, it appeared to decline with treatment and rebound with discontinuation of treatment. Corresponding changes were noted in the HIV immunocomplex dissociated (ICD) p24 antigen. One patient had a partial response, 11 patients had stable disease, and 5 patients had disease progression during the short period of treatment. The maximum tolerated dose for IL-4 in patients with advanced AIDS-related KS is 1.5 μg/kg/day. At this dose level, IL-4 is poorly tolerated and is not an effective KS treatment. Treatment of the majority of patients is discontinued because of drug-related toxicity or because of disease progression. Future studies of IL-4 should be confined to studies of cytokine manipulation of the underlying HIV infection, as there appears to be little antitumor activity." @default.
• W1978590976 created "2016-06-24" @default.
• W1978590976 creator A5060217385 @default.
• W1978590976 creator A5069168548 @default.
• W1978590976 creator A5069517606 @default.
• W1978590976 creator A5083648953 @default.
• W1978590976 creator A5084784795 @default.
• W1978590976 creator A5091896275 @default.
• W1978590976 date "2002-11-01" @default.
• W1978590976 modified "2023-10-18" @default.
• W1978590976 title "Lack of Antitumor Activity and Intolerance of Interleukin-4 in Patients with Advanced HIV Disease and Kaposi's Sarcoma" @default.
• W1978590976 cites W1534106804 @default.
• W1978590976 cites W1963958510 @default.
• W1978590976 cites W2005091515 @default.
• W1978590976 cites W2025913976 @default.
• W1978590976 cites W2032438721 @default.
• W1978590976 cites W2034942334 @default.
• W1978590976 cites W2049070399 @default.
• W1978590976 cites W2065537276 @default.
• W1978590976 cites W2088907297 @default.
• W1978590976 cites W2090702421 @default.
• W1978590976 cites W2121632877 @default.
• W1978590976 cites W2144492440 @default.
• W1978590976 cites W2160945301 @default.
• W1978590976 cites W2183091990 @default.
• W1978590976 cites W2190356106 @default.
• W1978590976 cites W2516029 @default.
• W1978590976 doi "https://doi.org/10.1089/10799900260442575" @default.
• W1978590976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12513914" @default.
• W1978590976 hasPublicationYear "2002" @default.
• W1978590976 type Work @default.
• W1978590976 sameAs 1978590976 @default.
• W1978590976 citedByCount "6" @default.
• W1978590976 countsByYear W19785909762018 @default.
• W1978590976 countsByYear W19785909762021 @default.
• W1978590976 countsByYear W19785909762023 @default.
• W1978590976 crossrefType "journal-article" @default.
• W1978590976 hasAuthorship W1978590976A5060217385 @default.
• W1978590976 hasAuthorship W1978590976A5069168548 @default.
• W1978590976 hasAuthorship W1978590976A5069517606 @default.
• W1978590976 hasAuthorship W1978590976A5083648953 @default.
• W1978590976 hasAuthorship W1978590976A5084784795 @default.
• W1978590976 hasAuthorship W1978590976A5091896275 @default.
• W1978590976 hasConcept C126322002 @default.
• W1978590976 hasConcept C142724271 @default.
• W1978590976 hasConcept C143998085 @default.
• W1978590976 hasConcept C150903083 @default.
• W1978590976 hasConcept C203014093 @default.
• W1978590976 hasConcept C207001950 @default.
• W1978590976 hasConcept C2778256501 @default.
• W1978590976 hasConcept C2778690821 @default.
• W1978590976 hasConcept C2779134260 @default.
• W1978590976 hasConcept C2779236070 @default.
• W1978590976 hasConcept C2779399171 @default.
• W1978590976 hasConcept C29730261 @default.
• W1978590976 hasConcept C3018958071 @default.
• W1978590976 hasConcept C535046627 @default.
• W1978590976 hasConcept C71924100 @default.
• W1978590976 hasConcept C86803240 @default.
• W1978590976 hasConcept C8891405 @default.
• W1978590976 hasConcept C90924648 @default.
• W1978590976 hasConceptScore W1978590976C126322002 @default.
• W1978590976 hasConceptScore W1978590976C142724271 @default.
• W1978590976 hasConceptScore W1978590976C143998085 @default.
• W1978590976 hasConceptScore W1978590976C150903083 @default.
• W1978590976 hasConceptScore W1978590976C203014093 @default.
• W1978590976 hasConceptScore W1978590976C207001950 @default.
• W1978590976 hasConceptScore W1978590976C2778256501 @default.
• W1978590976 hasConceptScore W1978590976C2778690821 @default.
• W1978590976 hasConceptScore W1978590976C2779134260 @default.
• W1978590976 hasConceptScore W1978590976C2779236070 @default.
• W1978590976 hasConceptScore W1978590976C2779399171 @default.
• W1978590976 hasConceptScore W1978590976C29730261 @default.
• W1978590976 hasConceptScore W1978590976C3018958071 @default.
• W1978590976 hasConceptScore W1978590976C535046627 @default.
• W1978590976 hasConceptScore W1978590976C71924100 @default.
• W1978590976 hasConceptScore W1978590976C86803240 @default.
• W1978590976 hasConceptScore W1978590976C8891405 @default.
• W1978590976 hasConceptScore W1978590976C90924648 @default.
• W1978590976 hasIssue "11" @default.
• W1978590976 hasLocation W19785909761 @default.
• W1978590976 hasLocation W19785909762 @default.
• W1978590976 hasOpenAccess W1978590976 @default.
• W1978590976 hasPrimaryLocation W19785909761 @default.
• W1978590976 hasRelatedWork W1993985418 @default.
• W1978590976 hasRelatedWork W2043862405 @default.
• W1978590976 hasRelatedWork W2047209980 @default.
• W1978590976 hasRelatedWork W2052769723 @default.
• W1978590976 hasRelatedWork W2377314317 @default.
• W1978590976 hasRelatedWork W2418031874 @default.
• W1978590976 hasRelatedWork W3017248443 @default.
• W1978590976 hasRelatedWork W3213011254 @default.
• W1978590976 hasRelatedWork W2185732136 @default.
• W1978590976 hasRelatedWork W2396811992 @default.
• W1978590976 hasVolume "22" @default.
• W1978590976 isParatext "false" @default.
• W1978590976 isRetracted "false" @default.
• W1978590976 magId "1978590976" @default.

• next